

# ASX release

2 March 2026

## Change of Director's Interest – Lisa McIntyre

In accordance with the Listing Rules, Medibank attaches an Appendix 3Y – Change of Director's Interest Notice for Lisa McIntyre for release to the market.

This document has been authorised for release by Ashley Spencer, General Counsel – Health, Governance & Excellence Hubs.

### For further information please contact:

#### For media

Emily Ritchie  
Senior Executive, External Affairs  
M: +61 429 642 418  
E: [Emily.Ritchie@medibank.com.au](mailto:Emily.Ritchie@medibank.com.au)

#### For investors/analysts

Colette Campbell  
Senior Executive, Investor Relations  
M: +61 475 975 770  
E: [Investor.Relations@medibank.com.au](mailto:Investor.Relations@medibank.com.au)

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity: MEDIBANK PRIVATE LIMITED</b>
<b>ABN: 47 080 890 259</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Lisa Margaret McIntyre
<b>Date of last notice</b>	20 November 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Interest in Medibank Private Limited Ordinary Shares (' <i>Ordinary Shares</i> ') held by 21 Cows Pty Ltd <Goodman McIntyre S/F A/C>
<b>Date of change</b>	23 February 2026
<b>No. of securities held prior to change</b>	Nil
<b>Class</b>	Ordinary Shares
<b>Number acquired</b>	22,370 Ordinary Shares
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	22,370 Ordinary Shares at \$4.48 per share
<b>No. of securities held after change</b>	22,370 Ordinary Shares

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market purchase of Ordinary Shares
---	---------------------------------------

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

#### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.